Top

Published in:

01-04-2008 | Original Article

Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats

Authors: Masaharu Onoue, Akinobu Kurita, Shoichi Kado, Tsuneo Matsumoto, Norimasa Kaneda, Kazumi Uchida, Ikuo Kato, Teruo Yokokura

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2008

Abstract

We assessed the involvement of UDP-glucuronosyltransferase (UGT) activity in episodes of irinotecan hydrochloride (CPT-11)-induced delayed-onset diarrhea using a mutant rat strain with an inherited deficiency of UGT1A (Gunn rats). Gunn rats exhibited severe diarrhea after the intravenous administration of CPT-11 at a dose of 20 mg/kg, whereas Wistar rats did not. In the epithelium of the small intestine and cecum in Gunn rats, the shortening of villi, degeneration of crypts, and destruction of the nucleus were observed. The AUC, MRT, and t _1/2 of CPT-11, and the AUC of 7-ethyl-10-hydroxycamptothecin (SN-38) in plasma were, respectively, 1.6-fold, 1.5-fold, 1.7-fold, and 6.5-fold higher, and the cumulative biliary excretion rate of SN-38 was 2.3-fold higher, in Gunn rats than Wistar rats. SN-38 glucuronide excreted via bile in Wistar rats was not de-conjugated in the small intestinal lumen. The SN-38 AUC values in small intestinal tissues were also 5.0 to 5.8-fold higher in Gunn rats than Wistar rats. In conclusion, Gunn rats developed severe delayed-onset diarrhea after i.v. administration of CPT-11 at a much lower dose. Severe intestinal impairments would be induced in Gunn rats through exposure to SN-38 at high levels for a long period mainly via the intestinal lumen and partially via the bloodstream. These results clarified that the deficiency of UGT activity contributed greatly to the induction of the CPT-11-induced delayed-onset diarrhea and epithelial impairment in the intestine. In the clinic, great care is needed when using chemotherapy with CPT-11 in patients with poor UGT activity.

Abigerges D, Armand J-P, Chabot GG, da Costa L, Fadel E, Cote C, Hérait P, Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446–449PubMedCrossRef

Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921–6926PubMed

Atsumi R, Suzuki W, Hakusui H (1991) Identification of metabolites of irinotecan, a new derivative of camptothecin, in the rat bile and its biliary excretion. Xenobiotica 21:1159–1169PubMed

Chowdhury JR, Kondapalli R, Chowdhury NR (1993) Gunn rat: a model for inherited deficiency of bilirubin glucuronidation. Adv Vet Sci Comp Med 37:149–173PubMed

Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer (see comment citation in Medline). J Clin Oncol 10:16–20PubMed

Furuta T, Yokokura T, Mutai M (1998) Antitumor activity of CPT-11 against rat Walker 256 carcinoma (in Japanese). Jpn J Cancer Chemother 15:2757–2760

Gandia D, Abigerges D, Armand J-P, Chabot GG, da Costa L, de Forni M (1993) CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 11:196–197PubMed

Gange JF, Montminy V, Belanger P, Journault K, Guillemette C (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroycamptothecin (SN-38). Mol Pharmacol 62:608–617CrossRef

Gibson RJ, Bowen JM, Inglis MRB, Cummins AG, Keefe DMK. (2003) Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 18:1095–1100PubMedCrossRef

10.

Goncalves E, da Costa L, Abigerges D, Armand J-P (1995) A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11. J Clin Oncol 13:2144–2146PubMed

11.

Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723–3725PubMed

12.

Gupta E, Wang X, Ramirez J, Ratain MJ (1997) Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 39:40–444CrossRef

13.

Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382–1388PubMedCrossRef

14.

Kaneda N, Yokokura T (1990) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721–1725PubMed

15.

Kawato Y, Tsumori T, Akahane K, Sekiguchi M, Sato K (1990) Inhibitory effect of CPT-11, a derivative of camptothecin, on acetylcholinesterase, and its binding ability to acetylcholine receptors (in Japanese). Clin Rep 24:7407–7412

16.

Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187–4191PubMed

17.

Kitagawa C, Ando M, Ando Y, Sekido Y, Wakai K, Imaizumi K, Shimokata K, Hasegawa Y (2005) Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet Genomics 15:35–41PubMedCrossRef

18.

Kojima A, Shinkai T, Saijo N (1993) Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes. Jpn J Clin Oncol 23:116–122PubMed

19.

Komatsu Y, Takei M, Yuki S, Fuse N, Furukawa S, Kato T, Takeda H, Kato M, Asaka M (2005) Treatment of a Gilbert’s syndrome patient with irinotecan, leucovorin and 5-fluorouracil. J Chemother 17:111–114PubMed

20.

Kudoh S, Fukuoka M, Masuda N, Yoshikawa A, Kusunoki Y, Matsui K, Negoro S, Takifuji N, Nakagawa K, Hirashima T (1995) Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res 86:406–413PubMed

21.

Kunimoto T, Nitta K, Tanaka T, Uehara M, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-(4-(1-piperidino)-1-piperidino) carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944–5947PubMed

22.

Kurita A, Kaneda N (1999) High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid phase extraction system, PROSPEKT. J Chromatogr B 724:335–344CrossRef

23.

Kurita K, Kado S, Kaneda N, Onoue M, Hashimoto S, Yokokura T (2000) Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats. Cancer Chemother Pharmacol 46:211–220PubMedCrossRef

24.

Mehra R, Murren J, Chung G, Smith B, Psyrri A (2005) Severe irinotacan-induced toxicies in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism. Clin Colorectal Cancer 5:61–64PubMedCrossRef

25.

Mehta VK, Cho C, Ford JM, Jambalos C, Poen J, Koong A, Lin A, Bastidas JA, Young H, Dunphy EP, Fisher G (2003) Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 55:132–137PubMedCrossRef

26.

Ohe Y, Sakai Y, Shinkai T, Eguchi K, Tamura T, Kojima A, Kunikane H, Okamoto H, Karato A, Ohmatsu H, Kanzawa F, Saijo N (1993) Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84:972–974CrossRef

27.

Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaru S, Ohta K (1990) An early II phase study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907–1912PubMed

28.

Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, Figg WD, Sparreboom A (2004) Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 44:854–860PubMedCrossRef

29.

Rothenberg ML, Kuhn JG, Burris HA, Morales MT, Nelson J, Eckardt JR, Rock MK, Terada K, von Hoff DD (1992) Phase I and pharmacokinetic trial of CPT-11 in patients with refractory solid tumors. Proc Am Soc Clin Oncol 11:2194–2204

30.

Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E (2004) Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10:5151–5159PubMedCrossRef

31.

Saliba F, Hagipantelli R, Misset J-L, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E (1998) Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 16:2745–2751PubMed

32.

Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K, Shinkai T, Tamura T, Ohe Y, Saijo N (1995) A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its metabolite SN-38. Jpn J Cancer Res 86:101–110PubMed

33.

Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11:909–913PubMed

34.

Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama T, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda Y, Muro K, Yoshida S (1997) Phase I–II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921–927PubMed

35.

Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, Kakihata K, Hirohashi M, Nomura M, Nagai E, Kamataki T (1995) Protective effects of Kampo medicine and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res 86:978–984PubMed

36.

Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride. Cancer Res 56:3752–3757PubMed

37.

Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y, Tamiya T, Tanizawa O, Sugawa T, Umesaki N, Sekiba K, Aono T, Nakano H, Noda K, Shirota M, Yakushiji M, Sugiyama T, Hashimoto M, Yajima A, Takamizawa H, Sonoda T, Takeda Y, Tomoda Y, Ohta M, Ozaki M, Hirabayashi K, Hiura M, Hatae M, Nishigaki K, Taguchi T (1991) A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research groups of CPT-11 in Gynecologic Cancers (in Japanese). Jpn J Cancer Chemother 18:1681–1689

38.

Tallman MN, Ritter JK, Smith PC (2005) Differential rates of glucuronidation for 7-ethyl-10-hydroxycamptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 33:977–983PubMedCrossRef

39.

Tallman MN, Miles KK, Kessler FK, Nielsen JN, Tian X, Ritter JK, Smith PC (2007) The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats. J Pharmacol Exp Ther 320:29–37PubMedCrossRef

Title: Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats
Authors: Masaharu Onoue
Akinobu Kurita
Shoichi Kado
Tsuneo Matsumoto
Norimasa Kaneda
Kazumi Uchida
Ikuo Kato
Teruo Yokokura
Publication date: 01-04-2008
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0512-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2008

A case of mixed adult Wilms’ tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO)

Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer

Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates

A late phase II study of S-1 for metastatic pancreatic cancer

A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization

A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer